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Abstract 
Background 
Osteosarcoma (OSA) represents the most common canine primary bone tumour. Despite 
several pathways have been investigated so far, few molecules have been identified as 
prognostic tools or potential therapeutic targets, and there is still the need to find out 
molecular pathways with specific influence over OSA progression to facilitate earlier 
prognosis and treatment. 
Aims of the present study were to evaluate the immunohistochemical pattern and levels of 
expression of a panel of molecules (survivin, β-catenin, caspase 3 -inactive and active forms- 
and p53) involved in cell cycle and apoptosis regulation in canine OSA samples, known to be 
of interest in the study also of human OSA, and to detect specific relations among them and 
with histological tumour grade, disease free interval (DFI) and overall survival (OS).  
Results 
Nuclear β-catenin immunostaining was detected in normal osteoblasts adjacent to the tumour, 
and in 47% of the cases. Cytoplasmic and/or membranous immunostaining were also 
observed. Nuclear survivin and p53 positive cells were found in all cases. Moderate/high 
cytoplasmic β-catenin expression (≥10% positive cells) was significantly associated with the 
development of metastasis (P  = 0.014); moderate/high nuclear p53 expression (≥10% positive 
cells) was significantly associated with moderate/high histological grade (P  = 0.017) and 
shorter OS (P = 0.049). Moderate/high nuclear survivin expression (≥15% positive cells) 
showed a tendency toward a longer OS (P  = 0,088).  
Conclusions 
The present results confirmed p53 as negative prognostic marker, while suggested survivin as 
a potential positive prognostic indicator, rather than indicative of a poor prognosis. The 
detection of nuclear β-catenin immunostaining in normal osteoblasts and the absent/low 
expression in most of the OSAs, suggested that this pathway could not play a major role in 
oncogenic transformation of canine osteoblasts. Further studies are needed to confirm these 
hypotheses. 
Background 
Osteosarcoma (OSA) represents the most common primary bone tumour of both dog [1] and 
childhood/adolescence [2]. Numerous histological and biological features have been shown 
to be shared by canine and human OSA to date [3-8], even if further studies are warranted to 
define more precisely similarities and differences of OSA in the two species, so as to really 
consider the dog as a valuable spontaneous tumour model for human OSA. Even if several 
pathways have been investigated in canine OSA so far, few molecules have been identified as 
prognostic tools or potential therapeutic targets [5,9-18]. Leading on from this, there is still 
the need to investigate molecular pathways with specific influence over canine OSA 
progression to facilitate earlier prognosis and treatment. 
The goal of the present study was to evaluate a panel of molecules involved in cell cycle and 
apoptosis regulation in canine OSA samples, known to be of interest in the study also of 
human OSA. Among these molecules, of particular significance, the role of β-catenin, and the 
related canonical Wnt pathway, has been largely investigated in human OSA [19-26], but its 
exact role during neoplastic transformation of osteoblast and OSA progression still remains a 
debated item. While several studies indicated an important contribution of the activation of 
the Wnt pathway in OSA development [19-25,27,28], Cai et al. [26] have recently argued the 
opposite, suggesting that the loss of Wnt pathway activity, which is required for osteoblast 
differentiation, may contribute to OSA development. Consequently, in contrast to other 
tumors, β-catenin might not play an oncogenic role in OSA cells [26,29]. 
Survivin has been recently proposed as a prognostic marker in human [30-35] and canine [36] 
OSA, but contrasting results have been observed concerning the relation between its 
subcellular localization and a favourable or poor prognosis. One of the most important 
aspects of the study of survivin expression in cancer is related to its high cancer specificity 
and consequent potentia l role as therapeutic target [37,38]. Survivin has been identified as a 
target gene of the β-catenin pathway [39], and it acts as a cell cycle regulator and apoptosis 
inhibitor, even if different isoforms with different functions of the molecule have been 
described [40].  
Loss of p53 tumour suppressor gene functions have been frequently reported in OSA, and 
mutated p53 has been reported in both human and canine OSA [41]. An interaction between 
p53 and β-catenin pathway has been proposed to play a key role in osteoblast differentiation 
and maintenance of bone tissue homeostasis [42]. Furthermore, activation of the Wnt/β -
catenin signalling has been shown to cause p53 accumulation [43].  
The aims of the present study were to evaluate the immunohistochemical pattern and levels of 
expression of survivin, β-catenin, caspase 3 (inactive [procaspase 3] and active forms), and 
p53 in canine OSA samples, to reveal specific relations among them and with histological 
tumour grade, disease free interval (DFI) and overall survival (OS). The attempt is to 
contribute to a better understanding of both the pathogenesis of canine OSA and the role of 
the investigated molecules, in particular establishing their role as prognostic biomarkers 
and/or potential therapeutic targets. Interestingly, in this study, the expression of nuclear 
survivin was mainly found in less malignant OSA cases, and β-catenin did not seem to play a 
major role in oncogenic transformation of canine osteoblasts, while nuclear p53 was 
confirmed to represent a negative prognostic marker.  
Results 
Histological examination 
OSAs were classified according to WHO classification [44], as: 5 productive osteoblastic, 2 
non productive osteoblastic, 1 telengectatic, 2 mixed, 3 fibroblastic, 1 undifferentiated, 1 
chondroblastic, and 2 giant cell OSA. According to the Kirpensteijn’s grading system [45], 4 
cases were classified as grade I, 7 as grade II, and 6 as grade III OSA (Table 1).  
Table 1 Patients data 
 Breed Sex Age 
(years) 
Localization Histological 
type 
Post-surgical 
treatment 
DFI 
(days) 
Overall 
survival 
(days) 
Development 
of Metastasis 
Grade I          
n°1 New 
Found 
Land 
m 11 Left Proximal 
humerus 
fibroblastic 
osteosarcoma 
doxorubicin 1033 1033 No 
n°2 Belgian 
Shepherd 
Malinois 
m 6 Left distal 
tibia 
productive 
osteoblastic 
osteosarcoma 
cisplatin/doxorubicin 438 449 Yes 
n°3 Great 
Dane 
m 5 Left distal 
tibia 
fibroblastic 
osteosarcoma 
cisplatin/doxorubicin 1250 1250 No 
n°4 Mixed m 4 Left distal 
radius 
nonproductive 
osteoblastic 
osteosarcoma 
cisplatin/doxorubicin 214 1089 Yes 
Grade II          
n°5 Great 
Dane 
f 4 Right distal 
radius 
chondroblastic 
osteosarcoma 
cisplatin/doxorubicin 89 168 Yes 
n°6 Mixed m 7 Distal ulna mixed 
osteosarcoma 
cisplatin/doxorubicin 553 553 No 
n°7 Mixed f 8 Left Proximal 
humerus 
mixed 
osteosarcoma 
doxorubicin 503 503 No 
n°8 Rottweiler f 7 Right 
proximal 
femur 
poorly 
differentiated 
osteosarcoma 
doxorubicin 623 715 Yes 
n°9 German 
Sheperd 
m 8 Right 
proximal 
humerus 
fibroblastic 
osteosarcoma 
cisplatin/doxorubicin 496 496 No 
n°10 Maremma 
Sheepdog 
m 9 Right distal 
radius 
teleangectatic 
osteosarcoma 
cisplatin/doxorubicin 261 261 No 
n°11 Rottweiler f 7,5 Right distal 
radius 
productive 
osteoblastic 
osteosarcoma 
cisplatin/doxorubicin 391 391 No 
Grade III          
n°12 Boxer  f 8 Right distal 
radius 
productive 
osteoblastic 
osteosarcoma 
cisplatin/doxorubicin 103 169 Yes 
n°13 Great 
Dane 
m 10 Left distal 
radius 
productive 
osteoblastic 
osteosarcoma 
cisplatin/doxorubicin 210 242 Yes 
n°14 German 
Sheperd 
f 7 Left distal 
femur 
nonproductive 
osteoblastic 
osteosarcoma 
doxorubicin 309 335 Yes 
n°15 Rottweiler m 2,5 Distal radius giant cell type 
osteosarcoma 
cisplatin 75/167 211 Yes 
n°16 New 
Found 
Retriever 
m 7 Left Distal 
radius 
productive 
osteoblastic 
osteosarcoma 
cisplatin/doxorubicin 126 200 Yes 
n°17 Saint 
Bernard 
m 7 Left Distal 
radius 
giant cell type 
osteosarcoma 
cisplatin/doxorubicin 203 203 No 
Tumour grade, breed, sex, age, localization, histological type, post-surgical treatment, DFI, 
overall survival and development of metastasis of the cases included in the present study.  
β-catenin expression in canine OSA 
In normal osteoblasts surrounding bone trabeculae adjacent to the tumours, β-catenin showed 
an intense nuclear expression, and a less intense cytoplasmic-membranous expression (Figure 
1,a). In tumour cells, membranous β-catenin immunostaining was observed in 65% of the 
cases, inconsistent and multifocal (Figure 1,b), observed in 2/4 grade I, 5/7 grade II and 4/6 
grade III cases. Cytoplasmic staining was found in all the samples examinated (Figure 1, c). 
Nuclear localization was found in only 47% of the cases, observed in 2/4 grade I, 5/7 grade II 
and 1/6 grade III cases. The number of positive nuclei were very low: 50% grade I showed no 
positive nuclei and 50% a number of positive nuclei ranging from 0 to 10%; >0 and <10% 
positive nuclei were found in 5/7 of grade II; while 5/6 grade III did not show any positive 
nuclei (Tables 2 and 3). Most of the cases showing positive nuclei were fibroblastic OSA 
(Figure 1, d) (3 cases) or positive nuclei were found in spindle shaped cells present in the 
case of undifferentiated OSA, and in two cases of productive OSA. Positive nuclei were not 
found among giant cells, nor among cells of neoplastic emboli, where only cytoplasmic 
immunostaining was observed (Figure 2, a).  
Figure 1 Immunohistochemical β-catenin expression. a – Osteoblasts lining bone 
trabeculae surrounding neoplastic tissue. Intense nuclear immunostaining (arrows) (Bar. 40 
μm) b – Non-productive osteoblastic OSA. Multifocal and inconsistent membranous 
immunostaining (arrows) (Bar. 80 μm). c - Productive osteoblastic OSA. Diffuse cytoplasmic 
immunostaining (Bar. 40 μm). d – Fibroblastic OSA. Multifocal nuclear immunostaining 
(arrows) (Bar. 80 μm) 
Table 2 Immunohistochemical results 1 
  β-Catenin P53 Procaspase 3 Active 
Caspase 3 
Survivin 
GRADE N° Nuclear Membranous Cytoplasmic Cytoplasmic Nuclear 
I 4 2 (50%) 2 (50%) 4 (100%) 2 (50%) 4 (100%) 4 (100%) 4 (100%) 4 (100%) 
II 7 5 (71%) 5 (71%) 7 (100%) 6 (86%) 7 (100%) 7 (100%) 7 (100%) 7 (100%) 
III 6 1 (17%) 4 (67%) 6 (100%) 6 (100%) 6 (100%) 6 (100%) 6 (100%) 6 (100%) 
Positive samples for each molecules investigated grouped in different grades, according to 
Kirpensteijn’s grading system [45]. 
Table 3 Immunohistochemical results 2 
Grade  β-catenin p53 
N M C 
I - - - - 
0 2 (50%) 2 (50%) - 2 (50%) 
>0 - <10% 2 (50%) 1 (25%) 1 (25%) 2 (50%) 
≥10 - <25% - - - - 
≥25 - <50% - 1 (25%) 1 (25%) - 
≥50%  - - 2 (50%) - 
II 
0 2 (28.6%) 1 (14.3%) - 1 (14.3%) 
>0 - <10% 3 (42.8%) 1 (14.3%) 2 (28.6%) 1 (14.3%) 
≥10 - <25% 1 (14.3%) 1 (14.3%) 2 (28.6%) 3 (42.8%) 
≥25 - <50% 1 (14.3%) 1 (14.3%) 1 (14.3%) 2 (28.6%) 
≥50%  - 2 (28.6%) 2 (28.6%) - 
III 
0 5 (83.3%) 2 (33.3%) - - 
>0 e <10% - 2 (33.3%) 1 (16.7%) - 
≥10 - <25% 1 (16.7%) 1 (16.7%) 2 (33.3%) 1 (16.7%) 
≥25 - <50% - 1 (16.7%) 2 (33.3%) 4 (66.6%) 
≥50%  - - 1 (16.7%) 1 (16.7%) 
Number of positive cases (and percentage) for each ranges of positive cells observed, 
grouped in different grades, according to Kirpensteijn’s grading system [45].  N: nuclear; M: 
membranous; C: cytoplasmic.  
Figure 2 Immunohistochemistry in neoplastic emboli. a – Numerous p53-positive nuclei 
(arrows) (Bar. 160 μm). b – Weak cytoplasmic and multifocal nuclear (arrows) survivin 
immunostaining (Bar. 80 μm). c – Weak β-catenin cytoplasmic and no nuclear and 
membranous immunostaining (Bar. 80 μm)  
By Fisher’s exact test moderate/high cytoplasmic β-catenin expression (≥10% positive cells) 
in the primary tumours was predictive of development of metastasis (P  = 0.014). No relations 
were found between the semi-quantitative evaluation of β-catenin and the OS by Kaplan-
Meier survival analysis.  
Survivin expression in canine OSA 
No staining was found in normal osteoblasts surrounding bone trabeculae adjacent to the 
tumours, while all samples investigated showed both nuclear and cytoplasmic survivin 
immunostaining. Cytoplasmic survivin expression was very high (≥75% positive cells) in all 
the cases evaluated. Nuclear staining was more intense than cytoplasmic, with positive 
mitotic figures observed among all the tumours (Figure 3, a). Positive nuclei were also 
multifocally and inconsistently found in the giant cells. Numerous positive nuclei were 
present among cells of neoplastic emboli (Figure 2, b). 
Figure 3 Survivin and p53 immunohistochemical expression. a – Productive osteoblastic 
OSA. Multifocal survivin nuclear immunostaining (arrows) (Bar. 80 μm). b – Productive 
osteoblastic OSA. Numerous p53 positive nuclei (arrows) (Bar. 40 μm)  
Survivin nuclear expression ranged from 55.55% to 3.86%, with a mean value within the 
three different groups of 38.22% ± 17.5 (grade I), 16.56% ± 7.9 (grade II) and 13.59% ± 9 
(grade III) (mean value ± standard deviation). Statistically significant correlation, using 
Pearson’s correlation coefficient, was observed between nuclear survivin expression and 
active caspase 3 expression (ρ = 0.696; P = 0.008), longer DFI (ρ = 0.741; P = 0.001) and OS 
(ρ = 0.748; P = 0.001); the relation between nuclear survivin expression and active caspase 3 
expression seems to be confirmed by the Kendall’s Taub non parametric test (τb = 0.513; P = 
0.015), while the same test gives less significant results with longer DFI (P  = 0.177) and OS 
(P = 0.150). The Kaplan-Meier analysis and Log-Rank test (P = 0.088) (Figure 4, a) showed a 
tendency toward a longer OS in subject with moderate/high nuclear survivin expression 
(≥15% positive cells).  
Figure 4 Kaplan-Meier plots showing influence on survival of survivin and p53.  (a) 
Nuclear survivin expression score ≥15% showed a tendency toward a longer survival time (P  
= 0,088). (b) P53 nuclear expression score ≥10% appeared to be significantly associated to a 
longer post-surgical OS (P = 0.049) 
p53 expression in canine OSA 
Positive nuclei were observed in 82% of cases, found in 2/4 grade I, 6/7 grade II and 6/6 
grade III cases (Tables 2 and 3). Most of giant cells were negative, and scattered positive 
nucleoli were also observed (Figure 3, b). Numerous cells within neoplastic emboli showed 
positive nuclei (Figure 2, c). 
A high nuclear p53 expression (≥25% positive cells) was significantly associated with a high 
histological grade (III) (P  = 0.035), while moderate/high nuclear expression (≥10% positive 
cells) was significantly associated with a moderate/high histological grade (II and III) (P = 
0.017) and longer OS (P  = 0.004). The Kaplan-Meier analysis and Log-Rank test (P = 0.049) 
also showed longer OS in subject having moderate/high nuclear p53 expression (≥10% 
positive cells) (Figure 4, b).  
Caspase 3 expression in canine OSA 
A diffuse procaspase 3 cytoplasmic immunostaining was found in all the cases investigated; 
while multifocal active caspase 3-positive nuclei were found in all the neoplastic tissues, but 
none in normal osteoblasts surrounding bone trabeculae adjacent to the tumours.  
Active caspase 3 expression ranged from 65.41% to 5.48%, with a mean value within the 
three different groups of 53.82% ± 16.4 (grade I), 30.41% ± 23.4 (grade II) and 13.78% ± 
14.4 (grade III) (mean value ± standard deviation). 
No relations were found between the semi-quantitative evaluation of procaspase 3 and active 
caspase 3 and the investigated clinico-pathological parameters. 
Discussion 
The present study demonstrated and confirmed the expression of several important molecules 
in canine OSA, showing a potential prognostic value of some of them, that could also be 
considered as possible candidates for a therapeutic target. 
Even though the importance of the Wnt/β-catenin pathway in bone development and 
homeostasis is well defined [46,47], the role of β-catenin in the development and progression 
of bone tumours is not completely known [48]. Since OSA formation is probably the result of 
an altered bone regulation, it seems likely that deregulation of the Wnt signalling could be 
associated with the pathogenesis of OSA. The presence of intense β-catenin-positive nuclei in 
normal osteoblasts observed in the present study would confirm the fundamental role of the 
Wnt/β-catenin pathway in the maintenance of these cells. Indeed, nuclear β-catenin 
expression has been considered a hallmark of activation of the Wnt/β-catenin pathway 
[26,49] or mutations of β-catenin or molecules of its degradation complex [50]. Rare or 
completely absent positive nuclei were observed in the most malignant cases examinated 
herein, even if no significant association with the OS was observed, as well as in neoplastic 
emboli, suggesting that neither mutations nor activation of the Wnt/β-catenin pathway would 
occur in these cells. In accordance with that, no mutation has been recently identified in 
canine β-catenin exon 3, similarly to human OSA [19], even if a limited number of cases 
were examinated, and a mainly cytoplasmic, but rare nuclear localization of the protein was 
detected [51]. Furthermore, no differences in nuclear β-catenin immunohistochemical 
expression were observed in samples obtained from two populations of canine OSA patients 
with normal or high level of serum alkaline phosphatase concentration [52], known to have 
negative prognostic value in canine osteosarcoma patients [53]. These results seem to be in 
agreement with recent investigations in human OSA [26], where no β-catenin nuclear 
expression was observed in 90% of human high grade OSA biopsies examinated and 
inhibition of the Wnt/β-catenin pathway has been demonstrated to be important in osteoblast 
neoplastic transformation [26]. These observations seemed to confirm the hypothesis that 
inactivation of the Wnt/β-catenin pathway could be essential in OSA progression, differently 
to what is usually observed in other cancers [54], opening to new potential therapeutic 
strategies. Specific small molecule compounds that activate Wnt/β-catenin signaling in a 
highly cell-type specific manner (human OSA U2OS cell line) have recently been identified 
[55], that could induce the activation of the Wnt/β-catenin pathway and provide new 
therapeutic opportunities. Interestingly, high β-catenin cytoplasmic expression rate was 
significantly related to the development of metastasis. High levels of cytoplasmic protein, in 
absence of nuclear staining, could be related to a reduced membranous β-catenin, reported to 
be associated to invasion and metastatic potential in human OSA [21], however, an inhibition 
of β-catenin nuclear translocation may also be hypothesized. 
Similarly to what has previously been observed in human [30,31] and canine [36] OSA, both 
cytoplasmic and nuclear survivin expression pattern was observed in canine OSA. 
Mechanisms controlling survivin nuclear and/or cytoplasmic localization in tumour cells are 
often a debated question, s ince the item could acquire a different prognostic significance 
depending on the tumour type [56]. Our results seem to be in contrast with a recent study in 
which a correlation between survivin immunohistochemical expression and histological grade 
and mitotic index has been reported in canine OSA tissue samples [36]. Similarly, divergent 
results have been published concerning the relation between survivin expression and 
malignancy of human OSA [30,32-34]. Disagreements could be related to the presence of 
several survivin isoforms, with different, even opposite, functions, and this might indicate 
different activities of survivin within the cell. In particular, two survivin variants potentially 
act in an opposite way to the other three variants, with a potential proapoptotic function: 
Survivin-2α may attenuate the anti-apoptotic activity of full length survivin [57], while 
survivin-deltaEx3 has been shown to have apoptotic functions [58]. Noteworthy, the 
polyclonal antibody used in the present study recognizes all survivin splice variants, and 
decreased nuclear survivin expression score was found among more malignant grade III cases 
of canine OSA, as well as higher nuclear survivin expression appeared to be related to a 
longer post-treatment OS, similarly to that observed by Trieb et al. [30] in the human 
counterpart. A significant association was revealed between nuclear survivin expression and 
the activation of caspase 3, most probably indicative of apoptotic pathway activation, further 
supporting the hypothesis that nuclear survivin expression could be considered a positive 
prognostic marker in canine OSA. Indeed, despite a diffuse cytoplasmic staining of its 
inactive form (procaspase 3) observed in all the cases examinated, a progressive decreasing 
of the active caspase 3 mean values was observed in OSA from grade I to III. 
Differently to primary tumours, a frequent nuclear survivin immunostaining was observed 
among neoplastic emboli, suggesting a different behaviour of the protein in OSA metastatic 
spread. Therefore, further investigations on survivin expression in metastatic OSA are 
warranted, in order to understand its functions and role in the response to postoperative 
chemotherapy, since adjuvant treatment is mainly aimed at controlling the metastatic disease, 
and survivin has been frequently associated to resistance to chemotherapy [59,60]. Recently, 
this has been demonstrated also in canine OSA cell lines (Abrams and D17), where after 
survivin inhibition an increase of chemosensitivity to both doxorubicin and carboplatin has 
been observed [36]. Survivin has been proposed as a valuable target for anticancer therapy 
[37], and several molecules with a direct or indirect effect on survivin expression have been 
identified to date, some of which have been tested in clinical trials with encouraging results 
[61]. Decreasing survivin expression through STAT3 [5,62] or Hsp90 [63] inhibition in 
canine OSA cell lines has been recently proposed as a possible new therapeutic approach.  
There is a strong evidence of the involvement of p53 mutations in the development of canine 
OSA [41,64,65], as well as in the human counterpart [66,67]. In the present study, highest 
levels of expression of nuclear p53 were significantly associated with a shorter post surgical 
OS, and appeared to be related to the development of metastasis, confirming the importance 
of p53 as a negative prognostic marker in canine OSA, in accordance to previous published 
data regarding canine OSA, suggesting that, similarly to human OSA [68,69], alterations in  
p53 functions are associated with highly aggressive tumour behaviour [70,71]. Deregulation 
of the p53-survivin subsystem has been proposed to play an important role in several tumour 
types [72], since, WTp53 is able to repress survivin expression at both the mRNA and protein 
level [40]. In spite of this, our results suggests that different mechanisms could regulate 
survivin expression in canine OSA. 
Conclusions 
Data obtained from the present immunohistochemical study suggest survivin as a potential 
positive prognostic marker, rather than a marker of poor prognosis, even if its presence in 
metastatic emboli suggests its possible involvement in the malignant progression of canine 
OSA. Further investigations, in particular on the expression and roles of its different 
isoforms, should be performed in order to clarify if survivin could represent a valid 
biomarker in this kind of tumour.  
Lastly, the present data suggest that β-catenin, a key molecule for normal osteoblast 
differentiation, could not play a key role in the neoplastic transformation of canine 
osteoblasts, as recently suggested in human OSA. Further studies should be done in order to 
confirm this hypothesis.  
Methods 
Tissue samples and clinical data 
This retrospective study looked at of 17 canine OSA surgical samples, provided by the 
Department of Animal Pathology, Faculty of Veterinary Medicine, University of Torino 
(Italy), for which survival data were also provided. All the dogs included in the present study 
had an appendicular OSA (histologically confirmed) at presentation and no evidence of 
metastasis. Clinical staging included history, physical exam, complete blood count, serum 
biochemical profile, urinalysis and abdominal ultrasound. Limb (latero-lateral [LL] and 
antero-posterior [AP] views) and chest (right and left LL, and dorso-ventral [DV] views) 
radiographic evaluation was performed to examine features and extension of the tumour and 
presence of lung metastasis, respectively. Computed Tomography was performed in case of 
radiographic suspicion of lung metastasis. Regional lymph nodes were aspirated and 
cytologically examined when enlarged at clinical palpation. Initial diagnosis of the tumour 
was attempted by fine needle aspiration and cytology but, for a more specific identification of 
the tumour type, a preoperative biopsy was obtained in all cases using a Jamshidi needle and 
submitted to histopathology. Histopathology was performed also on the entire tumour 
specimen (in case of limb amputation or limb sparing using an allograft to substitute the 
tumour segment) or on a sample of the tumour (in case of limb sparing using the pasteurized 
neoplastic autograft), in order to confirm the diagnosis [73,74]. All dogs included in the 
present study were surgically treated (amputation or limb sparing) before receiving adjuvant 
chemotherapy using doxorubicin (30 mg/m2, 4–5 administrations, 21 days apart) or cisplatin 
(70 mg/m2, 4–5 administrations, 21 days apart) as a single agent, or a combination of 
cisplatin and doxorubicin (4 cycles, 21 days apart, each cycle consisting of cisplatin 50 
mg/m2 at day 1 and doxorubicin 15 mg/m2 at day 2). One of the three chemotherapy 
protocols was chosen based on the dog clinical status and owners compliance, since no 
protocol has been demonstrated to be superior [75-78]. Besides, histopathological tumour 
grade never influenced the choice of the chemotherapeutic protocol adopted. Canine patients 
were clinically and radiographically examined every 3 months during the first year after the 
conclusion of chemotherapy and then every 6 months for a minimum of 2 years. DFI (disease 
free interval) was considered as the period in days from surgery to recurrence and/or 
metastasis development, while OS (overall survival) as the period in days from surgery to 
death for tumour-related causes; for dogs still alive at the time of writing, OS was the number 
of days from surgery to the last clinical examination (patients’ data are summarized in Table 
1). 
Histological examination 
All specimens were routinely fixed in 10% formalin, embedded in paraffin wax, and 4–5 μm-
thick sections were examined using haematoxylin and eosin (H&E) staining and visualized 
by light microscopy. Tumours were histologically classified according to the World Health 
Organization (WHO) criteria [44], and histological gra de was determined according to the 
system proposed by Kirpensteijn et al. [45]. 
Immunohistochemical examination 
Dewaxed and rehydrated tissue sections were immunostained by the streptavidin-biotin 
peroxidase complex (SAB) method, using specific primary ant ibodies (Abs) reported in Table 
4, incubated overnight in a humidified chamber at 4°C. Immunohistochemical analysis 
followed procedure as reported in previous studies [79]. Endogenous peroxidase was blocked 
with H2O2 3% in absolute methanol for 45 minutes. Antigen retrieval was undertaken by 
heat-treating sections in citrate buffer at pH 6 (β-catenin, caspase 3) or Tris-EDTA pH 9.0 
(p53) in a microwave oven for 5 min. (3 cycles) or in citrate buffer at pH 6 in a pressure 
cooker for 20 min. (survivin). Presence of antibody binding was visualized with 3-3’-
diaminobenzidine (DAB, D5905, Sigma-Aldrich, St. Louis, MO, USA) solution, which was 
applied for 5 min, followed by a light counterstain with Mayer’s haematoxylin (Merck, 
Darmstadt, Germany) for 1 min. Positive control slides were used for each Abs using a tissue 
of known pattern of expression of each molecules (Table 4). Anti-p53 antibody validation 
was performed using samples of human mammary carcinoma (Figure 5, a) and a samples of 
canine nail bed squamous cell carcinoma (SCC) (Figure 5, b) then used as positive control. A 
negative control was performed in all instances by omitting the primary antibody and 
incubating tissue sections with Tris Buffered Saline (TBS); for active caspase 3, an irrelevant 
antibody directed against an unrelated antigen (mouse anti human desmin monoclonal 
antibody – Dako, Glostrub, Denmark) was also used. 
Table 4 Primary antibodies used in immunohistochemical analysis 
MOLECULE TYPE OF Ab COMPANY WORKING 
DILUTION 
POSITIVE CONTROL 
β-catenin Rabbit PAb Santa Cruz 
Biotecnology 
1:250 Normal canine skin [80] 
Survivin Rabbit PAb NOVUS 
Biologicals 
0.7 μg/ml Canine cutaneous SCC [79] 
p53 Rabbit PAb NovoCastra  1:400 Canine nail bed SCC (Figure 2) 
Procaspase 3 Rat MAb NovoCastra  1:85 Normal canine tonsil [81] 
Active Caspase 3 Mouse MAb Oncogene 1:200 Canine breast carcinoma [81] 
Clonality, company, working dilutions and positive controls used for each antibody. PAb: 
polyclonal antibody; MAb: monoclonal antibody. SCC: squamous cell carcinoma. 
Figure 5 Positive control tissues for p53. a- Human mammary carcinoma. p53-positive 
nuclei (arrows) (Bar. 40 μm). b – Canine nail bed squamous cell carcinoma. Numerous p53-
positive nuclei (arrows) (Bar. 40 μm).  
Quantification of immunostaining and statistical analysis 
Neoplastic tissues were scored by two pathologists as follow.  
Survivin and caspase 3 expression was evaluated by counting the number of positive nuclei in 
10 HPF at 400X, counting approximately 1000 cells, and expressed as a percentage. 
Cytoplasmic survivin expression was diffusely present in 100% of the cases evaluated.  
For p53 only nuclear staining was considered as positive, since nuclear immunostaining is 
suggestive of its mutation [68]; β-catenin expression was classified as membranous (localised 
at cell-cell boundaries), cytoplasmic (uniformly distributed throughout the cytoplasm) and 
nuclear. A semi-quantitative immunohistochemical assessment was performed and samples 
were subdivided based on the protein expression levels in 4 ranges for β-catenin and p53 
(absent: no positive cells; low: >0% - <10% positive cells; moderate: ≥10% - <50% positive 
cells; high: ≥50% positive cells) and 5 ranges for procaspase 3 and survivin (absent: no 
positive cells; low: >0% - <10% positive cells; moderate: ≥10% - <50% positive cells; high: 
≥50% - <75% positive cells; very high ≥75% positive cells). 
Fisher's exact test was applied to evaluate the association between the expression levels of the 
investigated molecules and clinico-pathological parameters. Pearson correlation test and 
Kendall’s Taub test were applied to examine the relations between the expression levels of 
nuclear survivin and p53, DFI, OS. Kaplan Meier analysis was used to estimate survival, and 
the significances of the differences were determined by the Log-Rank test. For this purpose, 
the cases were grouped according to the expression score as follows: <10% positive cells 
(absent + low semiquantitative evaluation) versus ≥10% positive cells (moderate  + high 
semiquantitative evaluation) for p53 and β-catenin; <15% positive cells (absent + low 
semiquantitative evaluation) versus ≥15% positive cells (moderate  + high semiquantitative 
evaluation) for survivin; or <25% positive cells (absent/low + moderate semiquantitative 
evaluation) versus ≥25% positive cells (high semiquantitative evaluation). Analyses were 
performed using the IBM SPSS19 statistical software, and the conventional 5% level was 
used to define statistical significance.  
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